This is a working overview of 冻干粉, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Intravenous diazepam or lorazepam are first-line treatments for convulsive status epilepticus. Lorazepam is more effective than diazepam and intravenous phenytoin in the treatment of status epilepticus and has a lower risk of continuing seizures that might require additional medication. Lorazepam's anticonvulsant properties and pharmacokinetic profile make intravenous use reliable for terminating acute seizures, but induce prolonged sedation. Orally administered benzodiazepines, including lorazepam, are occasionally used as long-term prophylactic treatment of resistant absence seizures; because of gradual tolerance to their anti-seizure effects, benzodiazepines are not considered first-line therapies. Additionally, common seizure characteristics (e.g., hypersalivation, jaw-clenching, involuntary swallowing) pose some difficulties with regard to oral administration. Lorazepam's anticonvulsant and central nervous system depressant properties are useful for the treatment and prevention of alcohol withdrawal syndrome. In this setting, impaired liver function is not a hazard with lorazepam, since lorazepam does not require oxidation, in the liver or otherwise, for its metabolism. Lorazepam is noted as being the most tolerable benzodiazepine in those with advanced-stage liver disease.
In March 1929, the Grand Lodge of Cuba created a youth organization called the Young Fraternal Hope Association (AJEF) (Spanish: Asociación de Jóvenes Esperanza de la Fraternidad), whose original charter was valid until February 1936. On February 9, 1936, through the efforts of its founder Fernando Suárez Núñez, AJEF established its first Lodge, Logia Esperanza. AJEF comprised young men ages 14 to 21, and in time, it spread beyond Cuba, into Mexico and South America.
Alternatively, a chief resident may describe a resident who has been selected to extend his or her residency by one year and organize the activities and training of the other residents (typically in internal medicine and pediatrics). If a physician finishes a residency and decides to further his or her education in a fellowship, they are referred to as a "fellow". Physicians who have fully completed their training in a particular field are referred to as attending physicians, or consultants (in Commonwealth countries). However, the above nomenclature applies only in educational institutes in which the period of training is specified in advance. In privately owned, non-training hospitals, in certain countries, the above terminology may reflect the level of responsibility held by a physician rather than their level of education.
=== 2007–present: Software tools === In June 2007, Bio-Synthesis, Inc. unveiled a new online software tool called Protein Lounge which brought all of the vital and necessary databases to one place. The Protein Database contained all of the necessary information for proteins, such as datasheets, reviews, signaling pathway relation, disease relation, sequences, publications and reagent links. The database offered the most comprehensive gene/protein sequence pages which have all pertinent information needed to analyze any sequence.1 In January 2008, Bio-Synthesis, Inc. announced an exclusive scientific collaboration with Dr. Dante Marciani, a world-renowned expert in immune agonists. The collaboration was focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extended to proprietary compounds that down regulate The immunity, an area of significance in the treatment of chronic inflammatory conditions. 2 In May 2009, Bio-Synthesis, Inc. began Mitochondrial, or DNA, testing and offered it commercially. The DNA Identity Testing Laboratory at Bio-Synthesis, Inc. (BSI) is currently sequencing DNA samples for maternal lineage and criminal investigations.3 In February 2010, Bio-synthesis has been awarded a 2-year, $590,000, Small Business and Innovation Research (SBIR) Phase 1 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Sources: en.wikipedia.org
=== Mutations === Cystinosis is presented in patients with a range of CTNS mutations; as of 2017, over 100 have been identified. The most common mutation is a 57,257 base pair deletion commonly referred to as the 57 kb deletion. This was formally known as the 65 kb deletion; a misnomer originating from early incorrect estimates. Other reported mutations include other deletions, missense mutations, and in-frame deletions and insertions. The type and extent of mutation determines the type and severity of cystinosis in the carrier. This is a result of the degree of transport inhibition caused by the misfolding of cystinosin. For example, mild cystinosis is typically associated with mutations that do not affect the amino acids in the transmembrane domains of cystinosin. In contrast, infantile nephropathic cystinosis, the most severe form of the disease, is most commonly associated with a total loss of activity. Gene deletion resulting in the absence of either of the sorting motifs results in the delocalization of cystinosin to the cellular plasma membrane.
== PPIs binding mode == The disulfide binding of the inhibitor takes place in the luminal sector of the H+/K+ ATPase where 2 mol of inhibitor is bound per 1 mol of active site H+/K+ ATPase. All PPIs react with cysteine 813 in the loop between TM5 and TM6 on the H+/K+ ATPase, fixing the enzyme in the E2 configuration. Omeprazole reacts with cysteine 813 and 892. Rabeprazole binds to cysteine 813 and both 892 and 321. Lansoprazole reacts with cysteine 813 and cysteine 321, whereas pantoprazole and tenatoprazole react with cysteine 813 and 822. Reaction with cysteine 822 confers a rather special property to the covalently inhibited enzyme, namely irreversibility to reducing agents. The likely first step is binding of the prodrug protonated on the pyridine of the compound with cysteine 813. Then the second proton is added with acid transport by the H+/K+ ATPase, and the compound is activated. Recent data suggest the hydrated sulfenic acid to be the reactive species forming directly from the mono-protonated benzimidazole bound on the surface of the pump.
Pharmacy informatics is the combination of pharmacy practice science and applied information science. Pharmacy informaticists work in many practice areas of pharmacy, however, they may also work in information technology departments or for healthcare information technology vendor companies. As a practice area and specialist domain, pharmacy informatics is growing quickly to meet the needs of major national and international patient information projects and health system interoperability goals. Pharmacists in this area are trained to participate in medication management system development, deployment, and optimization.
Surgical specialties focus on manually operative and instrumental techniques to treat disease. Medical specialties that focus on the diagnosis and non-surgical treatment of disease. Diagnostic specialties focus more purely on diagnosis of disorders.
== Distinctions == Hofmann was the founder and the director of Protein Research Laboratory at the School of Medicine at University of Pittsburgh, a member of the National Academy of Sciences, Professor Emeritus of Experimental Medicine and Biochemistry at the University of Pittsburgh School of Medicine, and a member of American Association for the Advancement of Science.
Sources: en.wikipedia.org
== Mechanism == The mechanism for MMP-3 is a variation on a larger theme seen in all matrix metalloproteinases. In the active site, a water molecule is coordinated to a glutamate residue (Glu202) and one of the zinc ions present in the catalytic domain. First, the coordinated water molecule performs a nucleophilic attack on the peptide substrate's scissile carbon while the glutamate simultaneously abstracts a proton from the water molecule. The abstracted proton is then removed from the glutamate by the nitrogen of the scissile amide. This forms a tetrahedral gem-diolate intermediate that is coordinated to the zinc atom. In order for the amide product to be released from the active site, the scissile amide must abstract a second proton from the coordinated water molecule. Alternatively, it has been shown for thermolysin (another metalloproteinase) that the amide product can be released in its neutral (R-NH2) form. The carboxylate product is released after a water molecule attacks the zinc ion and displaces the carboxylate product. The release of the carboxylate product is thought to be the rate-limiting step in the reaction. In addition to the water molecule directly involved in the mechanism, a second water molecule is suggested to be a part of the MMP-3 active site. This auxiliary water molecule is thought to stabilize the gem-diolate intermediate as well as the transition states by lowering the activation energy for their formation. This is demonstrated in the mechanism and reaction coordinate diagram below.
=== 2009, 2011, list of genera from Tucker & Tenorio, and Bouchet et al. === This is a list of what were recognized extant genera within Conidae as per J.K. Tucker & M.J. Tenorio (2009), and Bouchet et al. (2011): However, all these genera have become synonyms of subgenera within the genus Conus as per the revision of the taxonomy of the Conidae in 2015
=== Deka Base === The Deka Base (デカベース, Deka Bēsu) is the primary headquarters and base of operations of the S.P.D. Earth unit. It is equipped with Base Beams (ベースビーム, Bēsu Bīmu) and houses the Deka Machines. Additionally, the Deka Base can transform into either the Deka Base Crawler (デカベースクローラー, Deka Bēsu Kurōrā), which is equipped with the Crawler Beam (クローラービーム, Kurōrā Bīmu) cannons, or the humanoid Deka Base Robo (デカベースロボ, Deka Bēsu Robo), which is equipped with Finger Missiles (フィンガーミサイル, Fingā Misairu) and Knee Brace Beams (ニーブレスビーム, Nī Buresu Bīmu). Deka Base Robo's finisher is the Volcanic Buster (ヴォルカニック・バスター, Vorukanikku Basutā). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, the Deka Base has been rebuilt and renamed the Neo Deka Base (ネオデカベース, Neo Deka Bēsu). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, the Neo Deka Base has been rebuilt and renamed the Shin Neo Deka Base (シン・ネオデカベース, Shin Neo Deka Bēsu).
==== Film criticism ==== A significant number of users on TikTok, such as Juju Green, create content surrounding film criticism and easter eggs. However, as reported by The New York Times, these people often do not see themselves necessarily as film critics. These creators would often attend red carpet premieres of movies and interview the celebrities in attendance, which was the subject of significant debate as some considered the questions the creators asked to be disrespectful. By 2022, TikTok released a Showbiz List, highlighting individuals who were having a larger impact on the film industry. During the 2023 SAG-AFTRA strike, such influencers were told that they would be denied future entry into the union if they partnered with struck studios. This led many creators to stop creating new content which they were not already contractually obligated to create. Creators who posted saying that they would not be changing their content, such as Green, were met with significant criticism.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。